Efficacy and safety of native type II collagen in modulating knee osteoarthritis symptoms: a randomised, double-blind, placebo-controlled trial
Open Access
- 23 December 2022
- journal article
- research article
- Published by Wiley in Journal of Experimental Orthopaedics
- Vol. 9 (1), 1-9
- https://doi.org/10.1186/s40634-022-00559-8
Abstract
Knee osteoarthritis (OA) is the most common form of clinical arthritis in middle-aged and older individuals. Undenatured or native type II (TII) collagen derived from the chicken sternum has a good therapeutic effect on relieving severe pain of OA. Hence, the present study aimed to investigate the efficacy and safety of TII collagen (Native CT-II®) in individuals with knee OA. We conducted a 12-week randomised, double-blind, placebo-controlled, parallel-group study on 101 participants aged 40–65 years with knee OA. The participants were randomised to receive either TII collagen, glucosamine hydrochloride + chondroitin sulfate (G + C) or a placebo. The primary outcome was an improvement in the joint health of the participants assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) compared to G + C and placebo. Compared with the placebo group (n = 27), the TII collagen group (n = 29) and G + C group (n = 29) significantly improved the overall joint health measured by the change in WOMAC total score (week 12: TII collagen = -32.47 ± 19.51 and G + C = -33.74 ± 24.64 vs. placebo = -13.84 ± 17.61; p < 0.05) and relieved knee joint pain (week 12: TII collagen = -5.69 ± 3.66 and G + C = -6.03 ± 4.72 vs. placebo = -2.71 ± 3.95; p < 0.05). The statistically significant effect was observed as early as 4 weeks after the investigational product administration. Additionally, the TII collagen was more effective in improving the quality of life than the G + C. TII collagen not only has a significantly better effect and high safety profile for OA but also improves the quality of life of patients. Level 1 – Randomized Controlled Trial. ClinicalTrials.gov Identifier: NCT04470336; First submitted date: July 08, 2020; First posted date: July 14, 2020.Keywords
Funding Information
- Jiaxing Hengjie Biopharmaceutical Co. Ltd. , China
This publication has 30 references indexed in Scilit:
- Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimensAnnals Of The Rheumatic Diseases, 2014
- Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteersJournal of the International Society of Sports Nutrition, 2013
- Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?Arthritis Research & Therapy, 2012
- Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty AcidsInternational Journal of Rheumatology, 2011
- The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combinationOsteoarthritis and Cartilage, 2010
- Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trialInternational Journal of Medical Sciences, 2009
- A 32-Week Randomized, Placebo-Controlled Clinical Evaluation of RA-11, an Ayurvedic Drug, on Osteoarthritis of the KneesJCR: Journal of Clinical Rheumatology, 2004
- The effect of glucosamine supplementation on people experiencing regular knee pain * CommentaryBritish Journal of Sports Medicine, 2003
- Efficacy of a combination of FCHG49™ glucosamine hydrochloride, TRH122™ low molecular weight sodium chondroitin sulfate and manganese ascorbate* in the management of knee osteoarthritisOsteoarthritis and Cartilage, 2000
- Impact of Joint Impairment on Longitudinal Disability in Elderly PersonsJournal of Gerontology, 1994